The recent review article, “Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus” in the November 15, 2017 Clinical Infectious Diseases, addresses the trends and current status of the etiology of Community Acquired Pneumonia (CAP). These data support the need for a pathogen-agnostic/host-based approach to the disease, such as BioAegis’ plasma gelsolin program. Three of the most recent studies, including the CDC’s EPIC Study published in July 2015 New England Journal of Medicine, underscore the failure to identify a causative pathogen in greater than 50% of the cases. Streptococcus pneumoniae remains the most commonly identified pathogen, although it is demonstrated in


MORRISTOWN, NJ and BOSTON, MA, (BIOAEGIS THERAPEUTICS) October 18, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity, announced that data demonstrating that “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” was presented during ID Week, on October 4-8, 2017 in San Diego, California. 

ID Week is the annual meeting sponsored by the IDSA, PIDSA, HIVMA & SHEA, organizations which represent infectious disease physicians and health care professionals.

Read the full press release here: BioAegis Therapeutics ID Week Poster

 


BOSTON, MA and MORRISTOWN, NJ (BIOAEGIS THERAPEUTICS) October 13, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity announced that Mark J. DiNubile has joined the organization as Chief Medical Officer.

Dr. DiNubile brings to BioAegis the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. Mark is a board-certified physician in Internal Medicine and the subspecialty of Infectious Diseases and Fellow of the Infectious Disease Society of America (FIDSA). He joins BioAegis after 16 years at Merck & Co., Inc. where he was primarily focused on the therapeutic areas of Infectious Diseases and Vaccines. He has extensively published on a diverse spectrum of medical and scientific topics.

Read the full press release here: BioAegis CMO DiNubile


BOSTON, MA, and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) September 30, 2017. BioAegis Therapeutics Inc. announced that founding scientist Dr. Thomas P. Stossel presented the 24th Annual William C. Maloney Lecture on September 28, 2017 in the Bornstein Amphitheater at the Brigham and Women’s Hospital. The invited lecture was entitled, “Can our 10th Most Abundant Plasma Protein (that you’ve never heard of) Prevent Sepsis?”

This lectureship was established in 1991 to honor William C. Moloney, MD, formerly the Director of the Hematology Division at the Brigham and Women’s Hospital.

Thomas P. Stossel, MD, BioAegis Therapeutics’ founding scientist, is the discover of gelsolin. Dr. Stossel is Professor of Medicine Emeritus, Harvard Medical School; American Cancer Society Clinical Research Professor and Senior Physician, Brigham and Women’s Hospital. He is the holder of numerous patents and author of more than 300 papers, studies, and reviews. He is also a member of The National Academy of Sciences, The American Academy of Arts and Sciences, and the National Academy of Medicine, currently the Editor-in-Chief of Current Opinion in Hematology and Past Editor of Journal of Clinical Investigation, Past President of the American Society of Hematology and the American Society of Clinical Investigation.

Dr. Stossel commented, “I am honored to participate in this esteemed lecture series. It is especially gratifying to share with my Harvard colleagues the potential for plasma gelsolin, a protein which has been shown to have the ability to mobilize the body’s immune system to fight infections well as prevent the spread of excess inflammation in settings that often lead to organ failure and ultimately sepsis.”


BioAegis Therapeutics, Inc. will present to investors at the Marcum Microcap Conference on June 15, 2017. This conference is a nationally recognized forum for private and publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. It draws over 2000 participants from the microcap community. BioAegis CEO, Susan Levinson, PhD, will be presenting.
When: Thursday, June 15, 2017, 4 PM
Where: Winter Garden Room, Grand Hyatt New York, New York, NY.